MIRM
Q4 2026 EPS Estimate
$-0.53
Nov 3, 2026 · Reports after close
Revenue Estimate
$178M
FY2028E EPS$1.85
FY2029E EPS$5.16

Analyst Sentiment

Wall St. Consensus
Buy
18 analysts·Moderate coverage
76
Score
18 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
16%
Buy
1794%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$118.00
+18.2%
Consensus
$137.50
+37.7%
Bull
$165.00
+65.3%
12-Month Target Range18 analysts
$118.00$137.50$165.00
Current $99.83Consensus
Current Price
$99.83
Upside to Consensus
$37.67

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+16.66%
EPS
FY2028
Rev+26.68%
EPS
FY2029
Rev+34.11%
EPS+179.22%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$697M$813M$1.03B$1.38B$1.77B
Low$691M$752M$914M$1.29B$1.65B
High$706M$845M$1.20B$1.48B$1.89B
EBITDA Avg$-396M$-462M$-586M$-786M$-1.01B
Low$-402M$-481M$-683M$-840M$-1.08B
High$-393M$-428M$-520M$-733M$-940M
EBIT Avg$-421M$-491M$-622M$-834M$-1.07B
Low$-426M$-510M$-725M$-892M$-1.14B
High$-418M$-454M$-552M$-778M$-998M
Net Income Avg$-773M$7M$193M$259M$406M
Low$-852M$-823M$25M$237M$371M
High$-694M$326M$223M$283M$443M
EPS Avg$-15.18$-0.78$1.85$5.16$8.09
Low$-16.97$-16.40$0.49$4.71$7.39
High$-13.83$6.50$4.43$5.63$8.83
Analysts (Rev / EPS)10 / 79 / 89 / 94 / 34 / 3
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$178M$183M$190M$197M$206M$218M
Low$175M$179M$184M$192M$200M$212M
High$180M$186M$194M$201M$211M$223M
EBITDA Avg$-101M$-104M$-108M$-112M$-117M$-124M
Low$-102M$-106M$-110M$-115M$-120M$-127M
High$-100M$-102M$-105M$-109M$-114M$-120M
EBIT Avg$-107M$-111M$-114M$-119M$-125M$-132M
Low$-109M$-112M$-117M$-122M$-127M$-134M
High$-106M$-108M$-111M$-116M$-121M$-128M
Net Income Avg$-33M$-40M$-21M$-18M$-16M$-5M
Low$-62M$-91M$-22M$-19M$-16M$-5M
High$-10M$-4M$-20M$-17M$-15M$-4M
EPS Avg$-0.53$-0.63$-0.34$-0.28$-0.25$-0.07
Low$-0.98$-1.43$-0.34$-0.29$-0.26$-0.07
High$-0.16$-0.07$-0.32$-0.27$-0.24$-0.07
Analysts (Rev / EPS)8 / 38 / 34 / 15 / 14 / 15 / 1

Earnings Surprises

Recent Analyst Actions

Aug 6, 2026Robert W. Baird
Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird
Target:$123.00
+28.2%from $95.91
Aug 6, 2026Morgan Stanley
Mirum Pharmaceuticals price target lowered to $137 from $150 at Morgan Stanley
Target:$137.00
+29.5%from $105.79
Aug 6, 2026RBC Capital
Mirum Pharmaceuticals price target lowered to $135 from $148 at RBC Capital
Target:$135.00
+27.6%from $105.79
Aug 6, 2026H.C. Wainwright
Mirum Pharmaceuticals price target lowered to $140 from $185 at H.C. Wainwright
Target:$140.00
+32.3%from $105.79
Jul 7, 2026RBC Capital
Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital
Target:$148.00
+21.4%from $121.91
Jun 15, 2026CLSA
Mirum Pharmaceuticals (MIRM) PT Raised to $146 at Citizens After ENDO Data Reveal
Target:$146.00
+47.0%from $99.34
Jun 11, 2026Morgan Stanley
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
Target:$150.00
+59.6%from $94.00
May 19, 2026Wolfe Research
Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Target:$145.00
+51.8%from $95.49
May 7, 2026RBC Capital
Mirum Pharmaceuticals price target raised to $142 from $128 at RBC Capital
Target:$142.00
+35.5%from $104.83
May 7, 2026Raymond James
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Target:$165.00
+63.5%from $100.92
May 7, 2026H.C. Wainwright
Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright
Target:$185.00
+68.1%from $110.08
May 7, 2026Evercore ISI
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
Target:$138.00
+25.4%from $110.08
May 7, 2026Stifel Nicolaus
Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel
Target:$136.00
+23.5%from $110.08
May 7, 2026Robert W. Baird
Mirum Pharmaceuticals price target raised to $129 from $112 at Baird
Target:$129.00
+17.2%from $110.08
May 5, 2026Morgan Stanley
Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley
Target:$140.00
+32.3%from $105.79
May 4, 2026H.C. Wainwright
Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright
Target:$175.00
+62.2%from $107.92
Apr 28, 2026Robert W. Baird
Mirum Pharmaceuticals price target raised to $112 from $95 at Baird
Target:$112.00
+21.1%from $92.48
Apr 27, 2026H.C. Wainwright
Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
Target:$150.00
+60.9%from $93.23
Mar 4, 2026Evercore ISI
Mirum Pharmaceuticals (MIRM) PT Raised to $126 at Evercore ISI
Target:$126.00
+41.0%from $89.37
Feb 26, 2026Leerink Partners
Mirum Pharmaceuticals (MIRM) PT Lowered to $118 at Leerink Partners
Target:$118.00
+27.2%from $92.78
Feb 26, 2026RBC Capital
RBC Capital Defending Mirum Pharmaceuticals (MIRM) Amid 15% Drop: 'Buying Opportunity Ahead of Multiple De-risked Catalysts'
Target:$128.00
+36.0%from $94.14
Feb 17, 2026RBC Capital
Mirum Pharmaceuticals initiated with an Outperform at RBC Capital
Target:$130.00
+26.4%from $102.83
Jan 26, 2026H.C. Wainwright
Mirum Pharmaceuticals price target raised to $130 from $102 at H.C. Wainwright
Target:$130.00
+37.9%from $94.29
Jan 20, 2026Evercore ISI
Mirum Pharmaceuticals price target raised to $101 from $94 at Evercore ISI
Target:$101.00
+10.8%from $91.13
Jan 13, 2026H.C. Wainwright
Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright
Target:$102.00
+14.0%from $89.50
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.